Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis

doi:10.5306/wjco.v6.i4.73

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10097)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

589

WORD

287

HTML

3688

Figures (1-4)

939

Tables (1-1)

578

Sum=6081

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1354

Download

2660

Sum=4014

Aug 10, 2015 (publication date) through Mar 1, 2026

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Meta-Analysis

World J Clin Oncol. Aug 10, 2015; 6(4): 73-79
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.73

Second-line treatments for advanced gastric cancer: Interpreting outcomes by network meta-analysis

Brigitta Badiani, Dario Maratea, Andrea Messori

Brigitta Badiani, Dario Maratea, Andrea Messori, HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy

Author contributions: Badiani B performed the literature search and conducted the Bayesian meta-analysis; Maratea D checked the information from the clinical trials and contributed to the writing of the manuscript; Messori A wrote the manuscript and supervised all phases of the research.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at andrea.messori.it@gmail.com

Correspondence to: Dr. Andrea Messori, PhD, HTA Unit, ESTAV Toscana Centro, Regional Health Service, Via San Salvi 12, 50100 Firenze, Italy. andrea.messori.it@gmail.com

Fax: +39-5-74701319

Received: February 12, 2015
Peer-review started: February 14, 2015
First decision: March 6, 2015
Revised: April 8, 2015
Accepted: May 16, 2015
Article in press: May 18, 2015
Published online: August 10, 2015
Processing time: 186 Days and 10.2 Hours

Core Tip

Core tip: We carried out a Bayesian network meta-analysis to evaluate second-line treatments for advancer gastric cancer. After scanning the literature up to February 2015, 7 randomized controlled trials were included in our meta-analysis in which the treatments for this disease condition and best supportive care (BSC) were evaluated according to overall survival (OS). Our meta-analysis investigated 21 direct or indirect comparisons. The difference in OS between paclitaxel vs BSC and ramucirumab + paclitaxel vs BSC was statistically significant, while the other comparisons showed no statistical difference. In conclusion, our results indicate that both paclitaxel and ramucirumab + paclitaxel determine a significant prolongation in survival in comparison with BSC.